Personalized Health Care (PHC) in Cancer - Genomic Biomarkers for Pharmaceutical Development - page 45

[49] Mok T, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Geitinib or carboplatin-paclitaxel in pulmo-
nary adenocarcinoma. N Engl J Med 2009;361:947-57.
[50] D'Addario G, Felip E, On behalf of the ESMO Guidelines Working Group Nonsmall cell lung cancer: ESMO
clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl. 2):ii39-40.
[51] Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 Update on diagnosis, monitoring, and manage-
ment. Am J Hematol 2012;87:1038-45.
[52] Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs. STI571 (IRIS)
8-year follow up: Sustained survival and low risk for progression of events in patients with newly diagnosed
chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:1126.
[53] Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Eficacy and safety of a speciic inhibi-
tor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-7.
[54] Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibi-
tion in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.
[55] Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival
in patients with advanced non-small-cell lung cancer harboring ALK gene rearrangement: a retrospective
analysis. Lancet Oncol 2011;12(11):1004-12.
[56] Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, et al. Rapid and dramatic radiographic
and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient
with non-small cell lung cancer. J Thorac Oncol 2010;5(12):2044-6.
[57] Forde PM, Rudin CM. Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother
2012;13(8):1195-201.
[58] Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell
lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27(26):4247-53.
[59] Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, et al. Identiication of novel isoforms of the
EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008;68(13):4971-6.
[60] Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, et al. The EML4-ALK fusion gene is involved
in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer
2009;115(8):1723-33.
[61] Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged
non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in
oncology. Oncologist 2012;17(11):1351-75.
[62] Diverio D, Riccioni R, Mandelli F, Lo Coco F. The PML / RAR alpha fusion gene in the diagnosis and monitor-
ing of acute promyelocytic leukemia. Haematologica 1995;80:155-60.
[63] Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia
through formation of homodimers. Mol Cell 2000;5:821-30.
[64] Zhou DC, Kim SH, Ding W, Schultz C, Warrell Jr RP, Gallagher RE. Frequent mutations in the ligand-binding
domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional
relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo . Blood
2002;99:1356-63.
[65] Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 2011;6:345-64.
[66] Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated
BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
[67] Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. Vemurafenib: the irst drug approved for BRAF-
mutant cancer. Nat Rev Drug Discov 2012;11(11):873-86.
[68] Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer
Cell 2002;2:5-7.
[69] Halait H, Demartin K, Shah S, Soviero S, Langland R, Cheng S, et al. Analytical performance of a real-time
PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel
BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol 2012;21:1-8.
[70] Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant
advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
[71] Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemu-
rafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.